Core Viewpoint - Hema Medical (03309) reported a 6.5% increase in stock price, reaching HKD 2.13, with a trading volume of HKD 6.7167 million following the release of its mid-year results for 2025 [1] Financial Performance - The company reported revenue of HKD 944 million for the first half of 2025, representing a year-on-year growth of 2.4% [1] - Profit attributable to equity holders was HKD 49.944 million, showing a significant year-on-year increase of 62.4% [1] Market Dynamics - The slight increase in revenue was attributed to rising demand for ophthalmic medical services in Hong Kong, which boosted revenue from ophthalmic services [1] - However, this growth was partially offset by a decline in revenue from dental and ophthalmic services in Shenzhen due to intense competition [1] Acquisition Announcement - Hema Medical announced an agreement to acquire 58% of the issued share capital of Hong Kong Endoscopy Examination and Treatment Centre Limited, which operates under the name "Hong Kong Endoscopy Centre" [1] - The acquisition is expected to be completed around October 2025 [1]